TY - JOUR
T1 - The lifetime cost of current human immunodeficiency virus care in the United States
AU - Schackman, Bruce R.
AU - Gebo, Kelly A.
AU - Walensky, Rochelle P.
AU - Losina, Elena
AU - Muccio, Tammy
AU - Sax, Paul E.
AU - Weinstein, Milton C.
AU - Seage, George R.
AU - Moore, Richard D.
AU - Freedberg, Kenneth A.
PY - 2006/11
Y1 - 2006/11
N2 - OBJECTIVE: We sought to project the lifetime cost of medical care for human immunodefiency virus (HIV)-infected adults using current antiretroviral therapy (ART) standards. METHODS: Medical visits and hospitalizations for any reason were from the HIV Research Network, a consortium of high-volume HIV primary care sites. HIV treatment drug regimen efficacies were from clinical guidelines and published sources; data on other drugs used were not available. In a computer simulation model, we projected HIV medical care costs in 2004 U.S. dollars. RESULTS: From the time of entering HIV care, per person projected life expectancy is 24.2 years, discounted lifetime cost is $385,200, and undiscounted cost is $618,900 for adults who initiate ART with CD4 cell count <350/μL. Seventy-three percent of the cost is antiretroviral medications, 13% inpatient care, 9% outpatient care, and 5% other HIV-related medications and laboratory costs. For patients who initiate ART with CD4 cell count <200/μL, projected life expectancy is 22.5 years, discounted lifetime cost is $354,100 and undiscounted cost is $567,000. Results are sensitive to drug manufacturers' discounts, ART efficacy, and use of enfuvirtide for salvage. If costs are discounted to the time of infection, the discounted lifetime cost is $303,100. CONCLUSIONS: Effective ART regimens have substantially improved survival and have increased the lifetime cost of HIV-related medical care in the U.S.
AB - OBJECTIVE: We sought to project the lifetime cost of medical care for human immunodefiency virus (HIV)-infected adults using current antiretroviral therapy (ART) standards. METHODS: Medical visits and hospitalizations for any reason were from the HIV Research Network, a consortium of high-volume HIV primary care sites. HIV treatment drug regimen efficacies were from clinical guidelines and published sources; data on other drugs used were not available. In a computer simulation model, we projected HIV medical care costs in 2004 U.S. dollars. RESULTS: From the time of entering HIV care, per person projected life expectancy is 24.2 years, discounted lifetime cost is $385,200, and undiscounted cost is $618,900 for adults who initiate ART with CD4 cell count <350/μL. Seventy-three percent of the cost is antiretroviral medications, 13% inpatient care, 9% outpatient care, and 5% other HIV-related medications and laboratory costs. For patients who initiate ART with CD4 cell count <200/μL, projected life expectancy is 22.5 years, discounted lifetime cost is $354,100 and undiscounted cost is $567,000. Results are sensitive to drug manufacturers' discounts, ART efficacy, and use of enfuvirtide for salvage. If costs are discounted to the time of infection, the discounted lifetime cost is $303,100. CONCLUSIONS: Effective ART regimens have substantially improved survival and have increased the lifetime cost of HIV-related medical care in the U.S.
KW - AIDS
KW - Computer simulation model
KW - Cost
KW - HIV
KW - Life expectancy
UR - http://www.scopus.com/inward/record.url?scp=33750562166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750562166&partnerID=8YFLogxK
U2 - 10.1097/01.mlr.0000228021.89490.2a
DO - 10.1097/01.mlr.0000228021.89490.2a
M3 - Article
C2 - 17063130
AN - SCOPUS:33750562166
SN - 0025-7079
VL - 44
SP - 990
EP - 997
JO - Medical care
JF - Medical care
IS - 11
ER -